Corixa, GSK Bulking Up Oncology Sales Forces In Preparation For Bexxar
Executive Summary
Corixa and GlaxoSmithKline are increasing their sales forces in anticipation of Bexxar approval
You may also be interested in...
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Corixa and GlaxoSmithKline will conduct a head-to-head study of their non-Hodgkin's lymphoma treatment Bexxar and Idec's Zevalin, Corixa told FDA's Oncologic Drugs Advisory Committee Dec. 17
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011